cosmin4000/iStock via Getty Images
Omeros Corporation (NASDAQ:OMER) said on Tuesday that the U.S. FDA has accepted the resubmitted label expansion application for narsoplimab, a treatment for transplant-associated thrombotic microangiopathy, which can occur after stem cell transplants. The biologics license application resubmission is classified as
Mumbai: Soaring gold prices have not deterred central banks from purchasing the precious metal as they resumed shopping in August,...
As the Premier League’s Chelsea was on its way to a shutout victory at the Club World Cup final in July, President Donald...
A lot is riding on the AI boom, and it isn’t just the stock market surge. AI is being touted...
Paramount said Monday that it has bought the news and commentary website The Free Press and installed its founder, Bari...
US stocks were mixed on Monday as the federal government shutdown entered another week, while a megadeal between AMD (AMD)...
Sebi chairman Tuhin Kanta Pandey on Monday said retail investors should avoid speculative trading in derivatives, underscoring the risks associated...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
